In the ever intensifying discussions about the cost of new, and very expensive (oncology) drugs, a widely heared argument from industry is that they are ‘obliged’ to their shareholders to perform financially this well. Otherwise they would not be able to attract investors and therefor their output of innovative medicines will be endangered.

An interesting development is that there is building up more pressure from big investors, like pension funds and ‘society sensitive’ banks, to also consider the effects on society as a whole of the strict financial focus Big Pharma feels it has to oblige to.

Can activistic share holders alter the direction of the developments?

Then they might also take in consideration that ‘inviting’ or pushing , Big Pharma to take active co-responsibilty for the Medication Safety related issues is a desirable societal goal aswell. GIMS can help!